CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Results of Operations and Financial Condition

CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition.
Story continues below

On March 29, 2019, CASI Pharmaceuticals, Inc. (the “Company”) issued a press release reporting its financial results for the three month period and year ending December 31, 2018. The press release is furnished as Exhibit99.1 to this Current Report on Form 8-K.

The information on this Current Report on Form 8-K (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

CASI Pharmaceuticals, Inc. Exhibit
EX-99.1 2 tv517396_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1     FOR IMMEDIATE RELEASE CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS RESULTS   ·Announced distribution partner for Melphalan Hydrochloride for Injection (EVOMELA®) to support commercialization in China following NMPA approval in December of 2018 ·Announced NMPA approval of CTAs to conduct confirmatory registration trials for vincristine sulfate LIPOSOME injection (MARQIBO®) and Ibritumomab Tiuxetan (ZEVALIN®) ·Announced plans to build GMP manufacturing site in Wuxi,…
To view the full exhibit click here


CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

An ad to help with our costs